 |
| 18-Jun-13 | Downgrade |
Barclays |
Equal Weight → Underweight |
|
|
| 17-May-13 | Reiterated |
Barclays |
Equal Weight |
$44 → $55 |
|
| 02-May-13 | Reiterated |
ISI Group |
Neutral |
$75 → $77.50 |
|
| 25-Jan-13 | Reiterated |
ISI Group |
Neutral |
$60.50 → $69.50 |
|
| 25-Jan-13 | Reiterated |
Barclays |
Equal Weight |
$41 → $44 |
|
| 07-Nov-12 | Reiterated |
ISI Group |
Hold |
$54.50 → $60 |
|
| 14-Jul-11 | Initiated |
BB&T Capital Mkts |
Buy |
$70 |
|
| 16-Feb-11 | Reiterated |
UBS |
Neutral |
$55 → $58 |
|
| 05-Nov-10 | Reiterated |
UBS |
Neutral |
$44 → $47 |
|
| 30-Jul-10 | Reiterated |
UBS |
Neutral |
$61 → $44 |
|
| 22-Sep-09 | Upgrade |
Jefferies & Co |
Hold → Buy |
$56 → $65 |
|
| 16-Jul-09 | Initiated |
JP Morgan |
Overweight |
|
|
| 21-May-09 | Initiated |
Leerink Swann |
Mkt Perform |
|
|
| 13-May-09 | Initiated |
Deutsche Securities |
Buy |
|
|
| 05-Feb-09 | Reiterated |
Jefferies & Co |
Hold |
$38 → $42 |
|
| 26-Jan-09 | Reiterated |
Jefferies & Co |
Hold |
$40 → $38 |
|
| 23-Dec-08 | Initiated |
Piper Jaffray |
Buy |
|
|
| 19-Dec-08 | Reiterated |
UBS |
Neutral |
$38 → $46 |
|
| 19-Dec-08 | Reiterated |
Jefferies & Co |
Hold |
$44 → $40 |
|
| 18-Dec-08 | Downgrade |
Ladenburg Thalmann |
Buy → Neutral |
|
|
|
|
| 12-Jun-13 06:49AM | Covance re-initiated with a Buy at Sterne Agee theflyonthewall.com |
| 11-Jun-13 10:13AM | Grab This Deal Even Lower Than Director Sheares Did at Forbes |
| 10-Jun-13 08:00AM | Covance To Present At The William Blair 33rd Annual Growth Stock Conference PR Newswire |
| 09-Jun-13 08:00AM | Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference PR Newswire |
| 30-May-13 01:40PM | Omnicare Unit Partners Drug Buster Zacks |
| 29-May-13 04:45PM | Covance Larger Than S&P 500 Component Patterson Companies at Forbes |
| 17-May-13 03:57PM | [video] Covance Not Cooling Off at TheStreet |
| 13-May-13 06:15PM | Cramer: This Fresh-Faced IPO Still a Buy at CNBC |
| 10:47AM | Covance To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference PR Newswire |
| 09:13AM | COVANCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Securit EDGAR Online |
| 10-May-13 01:04PM | COVANCE INC Financials EDGAR Online Financials |
| 09-May-13 06:56PM | Quintiles Climbs 5% In Debut In A Busy Day, Week For IPOs Investor's Business Daily |
| 11:45AM | Quintiles IPO Cleans Up As New Issues Multiply at Investor's Business Daily |
| 11:23AM | Quintiles shares rise 11 percent in market debut at Reuters |
| 11:21AM | Quintiles IPO Cleans Up As New Issues Multiply at Investor's Business Daily |
| 11:13AM | Pharmaceutical services provider Quintiles surges on first day of trading at theflyonthewall.com |
| 08-May-13 09:03PM | Quintiles IPO raises more-than-planned $947 mln as stocks rally at Reuters |
| 02:25PM | The Next Billionaire: A Statistician Who Changed Medicine at Forbes |
| 06-May-13 04:00PM | Covance To Present At The R. W. Baird 2013 Growth Stock Conference PR Newswire |
| 08:35AM | Covance Beats Earnings, Rev, Ups View Zacks |
| 03-May-13 02:36AM | COVANCE INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 02-May-13 06:00PM | Covance Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha |
| 07:30AM | Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call PR Newswire |
| 01-May-13 04:46PM | Covance Earnings: Everything You Must Know Now at Wall St. Cheat Sheet |
| 04:23PM | InPlay: Covance beats by $0.03, beats on revs; raises FY13 EPS in-line, revs in-line Briefing.com |
| 04:01PM | Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million PR Newswire |
| 09:37AM | COVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 07:07AM | Q1 2013 Covance Earnings Release - After Market Close CCBN |
| 26-Apr-13 12:38PM | Opportunities in Hepatitis C and Genomic Technologies: A Wall Street Transcript Interview with David Ferreiro, Executive Director and Senior Analyst at Oppenheimer & Co. Inc. Wall Street Transcript |
| 25-Apr-13 03:09PM | See How Covance Ranks Among Analysts' Top Picks With Strong Buyback Activity at Forbes |
| 17-Apr-13 02:43PM | The Healthy Play In Contract Research Organizations at Investopedia |
| 16-Apr-13 05:10PM | Covance Augments Singapore Facility Zacks |
| 01:00AM | Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients' Increased Asia Pacific Focus PR Newswire |
| 09-Apr-13 10:52AM | 5 Health Care Stocks Ready to Break Out at TheStreet |
| 03-Apr-13 11:04AM | Covance Inc. Invites You to Join the Webcast of Its First Quarter 2013 Financial Results Conference Call PR Newswire |
| 27-Mar-13 11:41AM | Covance Stock Hits New 52-Week High (CVD) at TheStreet |
| 26-Mar-13 09:45PM | System Says These 2 Relative Unknowns are the Best Mid-Cap Stocks to Buy The StreetAuthority Network |
| 09:45PM | System Says These 2 Relative Unknowns are the Best Mid-Cap Stocks to Buy |
| 08:15PM | System Says These 2 Relative Unknowns are the Best Mid-Cap Stocks to Buy The StreetAuthority Network |
| 08:15PM | System Says These 2 Relative Unknowns are the Best Mid-Cap Stocks to Buy |
| 06:13PM | System Says These 2 Relative Unknowns are the Best Mid-Cap Stocks to Buy The StreetAuthority Network |
| 20-Mar-13 09:54AM | Covance Stock Hits New 52-Week High (CVD) at TheStreet |
| 19-Mar-13 12:47PM | Europe Medical Device Space Less Volatile Than the U.S. Due to Domestic Market Being More Exposed to Swings in Consumer Sentiment, says Matt Miksic, Managing Director and Senior Research Analyst at Piper Jaffray & Co. Wall Street Transcript |
| 10:00AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 18-Mar-13 05:00PM | Covance Inc. (CVD): Today's Featured Health Services Winner at TheStreet |
| 10:06AM | On The Fly: Analyst Initiation Summary theflyonthewall.com |
| 12-Mar-13 03:45PM | Covance Reaches New 52-Week High (CVD) at TheStreet |
| 02:48PM | Reiterate Healthways at Neutral Zacks |
| 06-Mar-13 02:00PM | Long-Term Deals With Drug Makers Help Icon's Earnings at Investor's Business Daily |
| 05-Mar-13 01:04PM | COVANCE INC Financials EDGAR Online Financials |
| 27-Feb-13 12:27PM | COVANCE INC Files SEC form 10-K, Annual Report EDGAR Online |
| 26-Feb-13 06:30PM | Covance Inc. Presents at Citi 2013 Global Healthcare Conference, Feb-26-2013 02:15 PM at Seeking Alpha |
| 05:56PM | Covance Moves Up In Market Cap Rank, Passing Dun & Bradstreet at Forbes |
| 25-Feb-13 04:19PM | COVANCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; EDGAR Online |
| 01:48PM | HWAY and Wellmont Collaborate Zacks |
| 22-Feb-13 04:38PM | Covance To Present At The Citi 2013 Global Healthcare Conference PR Newswire |
| 20-Feb-13 07:58AM | Omnicare Tops Est., Higher Profit Zacks |
| 19-Feb-13 02:27PM | ESRX Reports In-Line 4Q Earnings Zacks |
| 14-Feb-13 02:56PM | Mixed 4Q for Charles River Zacks |
| 11-Feb-13 02:28PM | Healthways Agrees with Carondelet Zacks |
| 12:22PM | Covance To Present At The Leerink Swann Global Healthcare Conference PR Newswire |
| 06-Feb-13 11:11AM | 5 Stocks Hedge Funds Love -- and So Should You at TheStreet |
| 04-Feb-13 01:02AM | Covance: Making Bucks More Quickly at Motley Fool |
| 28-Jan-13 08:08AM | All-Front Easy Beat for Covance Zacks |
| 27-Jan-13 02:53PM | Covance Earnings Call Insights: Organic Margin Assumption and Central Lab Levels at Wall St. Cheat Sheet |
| 09:21AM | New Star Analyst Rankings for Covance Inc. Common Stock StarMine |
| 25-Jan-13 03:40PM | Covance Management Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha |
| 10:59AM | Briggs & Stratton Risk Remains Compelling and 4 Stock Analyses Turning Heads at Wall St. Cheat Sheet |
| 09:19AM | New Star Analyst Rankings for Covance Inc. Common Stock StarMine |
| 09:04AM | Covance Beats on Both Top and Bottom Lines at Motley Fool |
| 07:30AM | Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2012 Financial Results Conference Call PR Newswire |
| 24-Jan-13 04:36PM | COVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online |
| 04:13PM | InPlay: Covance beats by $0.02, beats on revs; guides Q1 EPS above consensus; guides FY13 EPS in-line Briefing.com |
| 04:03PM | Covance Reports Fourth Quarter Pro Forma Net Revenue Of $561 Million, Pro Forma EPS Of $0.73 And Adjusted Net Orders Of $769 Million PR Newswire |
| 07:07AM | Q4 2012 Covance Earnings Release - After Market Close CCBN |
| 23-Jan-13 01:25PM | See How Covance Ranks Among Analysts' Top Picks With Strong Buyback Activity at Forbes |
| 21-Jan-13 09:12AM | Will These Numbers from Covance Be Good Enough for You? at Motley Fool |
| 12-Jan-13 04:54AM | [$$] Research Reports at Barrons.com |
| 11-Jan-13 10:06AM | Apple Lowers Shipment Estimates and 4 Investor Insights Making Rounds at Wall St. Cheat Sheet |
| 07-Jan-13 10:33AM | Covance To Present At The 31st Annual J. P. Morgan Healthcare Conference PR Newswire |
| 03-Jan-13 02:38PM | PRXL Closes Buyout, Yields Outlook (revised) Zacks |
| 11:21AM | Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2012 Financial Results Conference Call PR Newswire |
| 08:38AM | BASi Introduces Culex NxT Zacks |
| 31-Dec-12 03:00PM | [$$] Contract Research Could Expand at Barrons.com |
| 07:00AM | Strengthening Moats Mean Improving Returns for CRO Investors Morningstar |
| 28-Dec-12 11:48AM | PRXL Closes Buyout; Yields Outlook Zacks |
| 10-Dec-12 03:02PM | TheStreet Ratings Top 10 Rating Changes at TheStreet |
| 09-Dec-12 08:31AM | China Biotech In Review: Roche Opens Sales HQ In Surprising Location at Seeking Alpha |
| 06-Dec-12 04:00AM | Covance Inc. Stock Upgraded (CVD) at TheStreet |
| 03-Dec-12 05:05PM | InPlay: Covance receives SFDA GLP Cerfification for its early development facility in Shanghai, China Briefing.com |
| 05:00PM | Covance Receives SFDA GLP Certification for Its Early Development Facility in Shanghai, China PR Newswire |
| 09:00AM | Covance Earns CEO Cancer Gold Standard Employer Accreditation PR Newswire |
| 26-Nov-12 04:44PM | Covance Larger Than S&P 500 Component Tenet Healthcare at Forbes |
| 25-Nov-12 01:14AM | Is Covance's Cash Flow Just For Show? at Motley Fool |
| 19-Nov-12 09:06AM | What Shorts Might Be Watching at Covance at Motley Fool |
| 14-Nov-12 01:04PM | COVANCE INC Financials EDGAR Online Financials |
| 12-Nov-12 10:03AM | Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference PR Newswire |
| 08-Nov-12 09:31AM | COVANCE INC Files SEC form 10-Q, Quarterly Report EDGAR Online |
| 07-Nov-12 05:16PM | SBA Communications Produces Solid Q3 and 3 Stock Analyses Buzzing Today at Wall St. Cheat Sheet |
| 02:10PM | SBA Communications Produces Solid Q3 and 3 Stock Analyses Buzzing Today at Wall St. Cheat Sheet |
|
|
| Covance Inc., a drug development services company, provides various early-stage and late-stage product development services primarily to the pharmaceutical, biotechnology, and medical device industries primarily in the United States and Europe. Its Early Development segment offers preclinical services, such as toxicology; pharmaceutical and nutritional chemistry, and food safety; purpose-bred animals for biomedical research; immunology, and polyclonal and monoclonal antibody; metabolism studies and pharmacokinetic screening; and bioanalytical testing services. It also provides clinical pharmacology services comprising first-in-human trials and proof of concept studies of new pharmaceuticals at its clinics. The company’s Late-Stage Development segment provides central laboratory services to biotechnology and pharmaceutical customers; and clinical development services, such as the full management of Phase II through IV clinical studies, study design and modeling, co-ordination of study activities, trial logistics, monitoring of study site performance, clinical data management and biostatistical analysis, and medical writing and regulatory services, as well as periapproval services. It also offers market access services, including reimbursement and healthcare economics consulting services, which comprise outcomes and pharmacoeconomic studies, reimbursement planning, reimbursement advocacy programs, risk evaluation and mitigation strategy services, registry services, specialty pharmacy services, and managed market contracting services; and clinical trial support services, such as cardiac safety services, and interactive voice and Web response services. The company also provides laboratory testing services to the chemical, agrochemical, and food industries. Covance Inc. was founded in 1987 and is headquartered in Princeton, New Jersey. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| SHEARES BRADLEY T | Director | Jun 06 | Buy | 73.87 | 200 | 14,773 | 5,920 | Jun 07 12:02 PM | | HELTON SANDRA L | Director | Jun 05 | Option Exercise | 46.40 | 2,800 | 129,920 | 15,688 | Jun 06 04:37 PM | | SHEARES BRADLEY T | Director | May 20 | Option Exercise | 0.00 | 1,600 | 0 | 7,320 | May 22 04:23 PM | | Scodari Joseph C | Director | May 20 | Option Exercise | 0.00 | 1,600 | 0 | 6,640 | May 22 04:20 PM | | MCCARTNEY JOHN | Director | May 20 | Option Exercise | 0.00 | 1,600 | 0 | 11,240 | May 22 04:17 PM | | COSTLEY GARY E | Director | May 20 | Option Exercise | 0.00 | 1,600 | 0 | 6,140 | May 22 04:14 PM | | HELTON SANDRA L | Director | May 20 | Option Exercise | 0.00 | 1,600 | 0 | 14,488 | May 22 04:11 PM | | BARCHI ROBERT | Director | May 20 | Option Exercise | 0.00 | 1,600 | 0 | 6,340 | May 22 04:06 PM | | LOVETT JAMES W | Corporate Sr. Vice President | May 15 | Option Exercise | 40.54 | 8,379 | 339,658 | 58,539 | May 17 04:35 PM | | LOVETT JAMES W | Corporate Sr. Vice President | May 15 | Sale | 77.00 | 10,259 | 789,943 | 48,280 | May 17 04:35 PM | | NUTT BRIAN H. | Principal Accounting Officer | Mar 21 | Option Exercise | 39.80 | 1,250 | 49,750 | 2,514 | Mar 21 04:28 PM | | NUTT BRIAN H. | Principal Accounting Officer | Mar 21 | Sale | 72.50 | 1,250 | 90,625 | 1,264 | Mar 21 04:28 PM | | MCCARTNEY JOHN | Director | Dec 13 | Option Exercise | 46.81 | 5,600 | 262,146 | 8,273 | Dec 14 03:53 PM | | HELTON SANDRA L | Director | Nov 23 | Option Exercise | 38.62 | 3,000 | 115,860 | 12,173 | Nov 26 04:34 PM | | LOVETT JAMES W | Corporate Sr. Vice President | Nov 16 | Option Exercise | 29.69 | 5,252 | 155,932 | 46,649 | Nov 20 04:08 PM | | Cimino Richard F | Corp. Executive Vice President | Nov 16 | Option Exercise | 41.71 | 12,000 | 500,532 | 76,203 | Nov 20 04:13 PM | | Cimino Richard F | Corp. Executive Vice President | Nov 16 | Sale | 54.00 | 15,000 | 810,000 | 61,203 | Nov 20 04:13 PM | | LOVETT JAMES W | Corporate Sr. Vice President | Nov 16 | Sale | 54.40 | 5,752 | 312,909 | 40,897 | Nov 20 04:08 PM | | Tanner Deborah L | Corp. Executive Vice President | Nov 16 | Sale | 54.55 | 2,962 | 161,577 | 45,322 | Nov 20 04:04 PM | | NUTT BRIAN H. | Principal Accounting Officer | Nov 15 | Sale | 54.05 | 231 | 12,486 | 543 | Nov 19 04:07 PM | | HERRING JOSEPH L | Chairman and CEO | Nov 06 | Option Exercise | 22.95 | 40,800 | 936,360 | 315,063 | Nov 08 04:08 PM | | HERRING JOSEPH L | Chairman and CEO | Nov 06 | Sale | 53.00 | 40,800 | 2,162,400 | 274,263 | Nov 08 04:08 PM | | KLITGAARD WILLIAM E | Corporate Sr. Vice President | Sep 19 | Option Exercise | 25.72 | 22,900 | 588,911 | 69,141 | Sep 20 04:23 PM | | KLITGAARD WILLIAM E | Corporate Sr. Vice President | Sep 19 | Sale | 47.16 | 31,900 | 1,504,557 | 37,241 | Sep 20 04:23 PM |
|
|
|
|
|
|
